![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication April 6, 2004.
Revised June 30, 2004.
Accepted for publication June 30, 2004.
Fatty acid amide hydrolase (FAAH) is the primary catabolic regulator of several bioactive lipid amides in vivo, including the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. Accordingly, inhibitors of FAAH are considered a potential therapeutic approach for the treatment of several nervous system disorders, including pain, anxiety, and insomnia. However, for FAAH inhibitors to achieve clinical utility, they must not only display efficacy in vivo, but also selectivity for this enzyme relative to the numerous other serine hydrolases present in mammalian proteomes. Here, we report a general strategy for evaluating the pharmacological activity and target specificity of FAAH inhibitors and its implementation to develop the first class of selective reversible inhibitors of this enzyme that are highly efficacious in vivo. Using a series of functional proteomics, analytical chemistry, and behavioral pharmacology assays, we have identified a class of 
-keto-heterocycles that show unprecedented selectivity for FAAH relative to other mammalian hydrolases, and, when administered to rodents, raise central nervous system levels of anandamide and promote cannabinoid receptor 1-dependent analgesia in several assays of pain sensation. These studies provide further evidence that FAAH may represent an attractive therapeutic target and describe a general route by which inhibitors of this enzyme can be optimized to achieve exceptional potency, selectivity, and efficacy in vivo.
Key words:
FAAH, analgesia, endocannabinoid, inhibitor, proteomics, reversible
This article has been cited by other articles:
|
|
 |
|
  M. Mileni, D. S. Johnson, Z. Wang, D. S. Everdeen, M. Liimatta, B. Pabst, K. Bhattacharya, R. A. Nugent, S. Kamtekar, B. F. Cravatt, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion PNAS, September 2, 2008; 105(35): 12820 - 12824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Merritt, B. R. Martin, C. Walters, A. H. Lichtman, and M. I. Damaj The Endogenous Cannabinoid System Modulates Nicotine Reward and Dependence J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 483 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dray Neuropathic pain: emerging treatments Br. J. Anaesth., July 1, 2008; 101(1): 48 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Solinas, G. Tanda, Z. Justinova, C. E. Wertheim, S. Yasar, D. Piomelli, S. K. Vadivel, A. Makriyannis, and S. R. Goldberg The Endogenous Cannabinoid Anandamide Produces {delta}-9-Tetrahydrocannabinol-Like Discriminative and Neurochemical Effects That Are Enhanced by Inhibition of Fatty Acid Amide Hydrolase but Not by Inhibition of Anandamide Transport J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Jhaveri, D. Richardson, D. A. Kendall, D. A. Barrett, and V. Chapman Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain J. Neurosci., December 20, 2006; 26(51): 13318 - 13327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Q. Wei, T. S. Mikkelsen, M. K. McKinney, E. S. Lander, and B. F. Cravatt A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals J. Biol. Chem., December 1, 2006; 281(48): 36569 - 36578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. La Rana, R. Russo, P. Campolongo, M. Bortolato, R. A. Mangieri, V. Cuomo, A. Iacono, G. M. Raso, R. Meli, D. Piomelli, et al. Modulation of Neuropathic and Inflammatory Pain by the Endocannabinoid Transport Inhibitor AM404 [N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide] J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1365 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaczocha, A. Hermann, S. T. Glaser, I. N. Bojesen, and D. G. Deutsch Anandamide Uptake Is Consistent with Rate-limited Diffusion and Is Regulated by the Degree of Its Hydrolysis by Fatty Acid Amide Hydrolase J. Biol. Chem., April 7, 2006; 281(14): 9066 - 9075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Varvel, B. F. Cravatt, A. E. Engram, and A. H. Lichtman Fatty Acid Amide Hydrolase (-/-) Mice Exhibit an Increased Sensitivity to the Disruptive Effects of Anandamide or Oleamide in a Working Memory Water Maze Task J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Glaser, S. J. Gatley, and A. N. Gifford Ex Vivo Imaging of Fatty Acid Amide Hydrolase Activity and Its Inhibition in the Mouse Brain J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1088 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mechoulam and D. G. Deutsch Toward an anandamide transporter PNAS, December 6, 2005; 102(49): 17541 - 17542. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
